Clinical trials
HER 2 Negative Breast Cancer clinical trials
Below are recruiting her 2 negative breast cancer clinical trials, each written for real people, not researchers. We’re tracking 913 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05035745RecruitingPhase 1/Phase 2
Selinexor plus talazoparib for advanced triple-negative breast cancer
This trial tests selinexor plus talazoparib in people with advanced, treatment-resistant solid tumors and, separately, advanced triple-negative breast cancer. It aims to see whether this combination can shrink tumors or slow their growth when standard options have not worked.
SingaporeAges 18–99 - NCT05491083RecruitingPhase 1/Phase 2
Pembrolizumab plus ADG106 for advanced triple-negative breast cancer
This early-phase study tests pembrolizumab (an immune therapy) combined with ADG106 in people with advanced solid tumors, and specifically triple-negative breast cancer. It looks at whether the treatment can shrink tumors and improve outcomes for cancers that are progressing despite prior therapy.
SingaporeAges 21–99 - NCT06767527RecruitingPhase 3
AK112 plus chemo for first-line triple-negative breast cancer
This trial tests a new immunotherapy drug called AK112 combined with chemotherapy (nab-paclitaxel) for people with advanced triple-negative breast cancer who haven't had treatment yet. The goal is to see if AK112 works better than a placebo at shrinking tumors and helping people live longer.
BeijingAges 18–75 - NCT06764940RecruitingPhase 2
Utidelone and capecitabine for HER2-negative breast cancer with brain metastases
This trial tests if the combination of Utidelone and capecitabine can shrink brain metastases in people with HER2-negative breast cancer. It is designed for those whose cancer has spread to the brain and who have not had many prior treatments.
Duarte, CaliforniaAges 18 years+ - NCT06771609RecruitingPhase 2
Immunotherapy plus low-dose chemo for advanced triple-negative breast cancer
This study tests a combination of an immunotherapy drug (PD-L1 inhibitor) with a special low-dose chemotherapy regimen (VEX) plus optional radiation for advanced triple-negative breast cancer. The goal is to see if this approach works better than standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06768931RecruitingPhase 2
Combination therapy before surgery for triple-negative breast cancer
This trial tests adding an immunotherapy drug to standard chemotherapy before surgery for triple-negative breast cancer. The goal is to see if this combination works better than chemotherapy alone.
Lanzhou, GansuAges 18 years+ - NCT06756932RecruitingPhase 1
Bcl-2 inhibitor combo for advanced HR+ breast cancer
This trial tests a new Bcl-2 inhibitor (BGB-21447) combined with other therapies for advanced HR+/HER2- breast cancer that has already been treated with hormone therapy and a CDK4/6 inhibitor. It aims to see if these combinations are safe and effective.
Iowa City, IowaAges 18 years+ - NCT06757634RecruitingPhase 3
A study of gedatolisib for first-line advanced breast cancer
This trial tests a new targeted therapy called gedatolisib for people with HR-positive, HER2-negative advanced breast cancer who have not yet received treatment for metastatic disease. It aims to see if adding this drug to standard hormone therapy can help control the cancer longer.
Jonesboro, ArkansasAges 18 years+ - NCT06744465Recruiting
Light-based monitoring for breast cancer during chemo
This study uses a special light-based device to monitor breast cancer during chemotherapy before surgery. It is for women with HER2-positive or triple-negative breast cancer who are planning chemotherapy first.
Indianapolis, IndianaAges 18 years+ - NCT06732323RecruitingPhase 3
Study of ESG401 for triple-negative breast cancer that has spread
This trial tests a new drug, ESG401, for people with triple-negative breast cancer that has come back or spread and cannot be removed by surgery. It compares ESG401 to standard chemotherapy options to see which works better.
BeijingAges 18 years+ - NCT06731140RecruitingPhase 2
Reversing immune resistance in HER2-negative breast cancer
This trial tests a new treatment to see if it can reverse resistance to immunotherapy in people with HER2-negative breast cancer. It's for patients whose cancer has gotten worse after immunotherapy.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT03740893RecruitingPhase 2
Test drug to block DNA damage in triple-negative breast cancer
This Phase 2 trial studies a treatment given around the time of breast surgery to help shrink or control residual (remaining) triple-negative breast cancer. It also checks biomarkers (lab signals) to understand who benefits, with some people receiving anti–PD-L1 immunotherapy and some not.
Bournemouth, DorsetAges 18 years+ - NCT06690840RecruitingPhase 2
Atezolizumab plus chemo for advanced triple-negative breast cancer
This trial tests atezolizumab (an immunotherapy) plus chemotherapy to activate immune cells in people with triple-negative breast cancer that has spread or cannot be removed. It is for those who have had immunotherapy before during early treatment but not for advanced disease.
Monza, MonzaAges 18 years+ - NCT06682793RecruitingPhase 1/Phase 2
Study of A2B395 therapy for solid tumors with EGFR and HLA loss
This trial tests a new cell therapy called A2B395 for cancers that have EGFR, a protein on the cell surface, and have lost a specific marker called HLA-A*02. The therapy uses specially engineered immune cells to target and kill these cancer cells. This may help patients with colorectal, lung, head and neck, breast, kidney, or other solid tumors that are no longer responding to standard treatments.
Gilbert, ArizonaAges 18 years+ - NCT06611813RecruitingPhase 2
Chemo plus immunotherapy for HR+/HER2- breast cancer
This trial tests whether adding an immunotherapy drug (toripalimab) to standard chemotherapy before surgery can help treat HR+/HER2- breast cancer. It is for women with early-stage breast cancer that has not spread to other parts of the body.
HangzhouAges 18–75 - NCT06680596Enrolling by invitationPhase 2
Blood test to find T-DXd candidates for breast cancer
This trial uses a blood test to look for tumor DNA in women with a certain type of advanced breast cancer (HR-positive, HER2-low). If the DNA doesn't disappear after starting standard hormone therapy with a CDK4/6 inhibitor, participants may be switched to a targeted drug called T-DXd (trastuzumab deruxtecan).
AmiensAges 18 years+ - NCT06678269RecruitingPhase 1
Abemaciclib and radiation for metastatic breast cancer
This trial tests whether a targeted therapy (abemaciclib) combined with focused radiation (SBRT) to a bone tumor can help people with advanced breast cancer. It is for patients whose cancer is hormone receptor positive and HER2 negative, and who will continue abemaciclib after radiation.
Basking Ridge, New JerseyAges 18 years+ - NCT06681064Recruiting
Tracking breast cancer changes during pre-surgery treatment
This study looks at how breast cancer changes while you are receiving chemotherapy or targeted therapy before surgery. The goal is to better understand which treatments work best for different types of breast cancer.
LondonAges 18 years+ - NCT06649331RecruitingPhase 2
Re-trying antibody-drug conjugates for advanced breast cancer
This study looks at whether giving a different antibody-drug conjugate (ADC) after a previous one can help people with advanced or metastatic breast cancer. It aims to find new options for patients who have already had ADC treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06650748Enrolling by invitationPhase 2
A study of hormone therapy with or without a targeted drug for breast cancer
This trial tests if adding a targeted drug (CDK4/6 inhibitor) to hormone therapy works better than hormone therapy alone for women with a certain type of breast cancer (HR+/HER2-). The study measures the activity of tumor cells (Ki-67) to help decide treatment.
BeijingAges 18–70 - NCT06637150RecruitingPhase 3
Dalpiciclib with hormone therapy for early breast cancer
This trial tests whether adding the drug dalpiciclib to standard hormone therapy improves outcomes for people with a certain type of early breast cancer (hormone receptor-positive, HER2-negative). It may help lower the risk of the cancer coming back.
ShanghaiAges 18–70 - NCT06635980RecruitingPhase 2
Radiation before or after breast cancer surgery
This trial compares two ways of giving radiation for breast cancer that has not spread: before or after surgery. It aims to see if giving radiation first might work as well or better.
Scottsdale, ArizonaAges 18 years+ - NCT06637306RecruitingEarly Phase 1
Testing dupilumab with chemo for advanced triple-negative breast cancer
This trial adds dupilumab (a targeted immune treatment) to standard chemotherapy before surgery for patients with advanced triple-negative breast cancer. The goal is to see if this combination helps shrink tumors more effectively.
New York, New YorkAges 18 years+ - NCT06631092RecruitingPhase 1/Phase 2
Personalized cancer vaccine with standard therapy for triple-negative breast cancer
This trial tests a personalized cancer vaccine (NECVAX-NEO1) given along with standard chemotherapy and immunotherapy before surgery for patients with triple-negative breast cancer. The vaccine is customized to target specific mutations in your tumor, aiming to boost your immune system and improve treatment outcomes.
ErlangenAges 18 years+
Hear when a new HER 2 Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her 2 negative breast cancer?
- Yes. Clin2 currently lists 913 recruiting her 2 negative breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her 2 negative breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her 2 negative breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- HR Positive/HER-2 Negative Breast Cancer
- Triple Negative Breast Cancer
- HER2-negative Breast Cancer
- Metastatic Triple-negative Breast Cancer
- Advanced Triple Negative Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.